Injectable Wegovy lowers BMI among children with obesity

Novo Nordisk (NVO) halted two late-stage heart disease studies, HERMES and ATHENA, citing expected futility. This follows the failure of its ZEUS trial in July. Analysts now consider IL-6 an invalid target for cardiovascular disease. Novo's stock dipped 2% to $45.59. The ARTEMIS trial continues, with results expected in early 2024.

Novo Nordisk (NVO) reported positive results from its STEP Young Phase 3 trial, showing significant BMI reduction in children aged 6 to under 12 with obesity using semaglutide. 40.4% of treated children achieved non-obese status by week 68, compared to 0% in the placebo group. The drug's safety profile aligned with previous studies. NVO shares were down 1.85% premarket.

Novo Nordisk (NVO) reported positive late-stage trial results for Wegovy in children aged 6 to 12, with 40.4% no longer classified as obese after 68 weeks. The trial met its primary endpoint, showing greater BMI reduction vs. placebo. The company aims to expand Wegovy's market, though regulatory approval and long-term safety data are pending. Investors see potential long-term growth but note near-term uncertainties.

Novo Nordisk reported that its once-weekly semaglutide, combined with lifestyle changes, reduced BMI more than placebo in children aged 6 to under 12 with obesity. The phase 3 STEP Young trial showed 40.4% of semaglutide participants were no longer classified as obese after 68 weeks, compared to 0% on placebo. The company reported no new safety concerns. Novo Nordisk develops medicines for diabetes, obesity, and other chronic diseases, with semaglutide marketed in several products.

Novo Nordisk (NVO) reported that its semaglutide treatment helped 40.4% of children in the STEP Young trial move below the obesity threshold. The trial met its primary endpoint, showing greater BMI reduction than placebo. NVO shares fell 1.92% to $46.60. No new safety concerns were reported. Results will be presented at ObesityWeek 2026.

Novo Nordisk reported STEP Young phase 3 trial results, showing 40.4% of children aged 6-12 with obesity treated with semaglutide were no longer classified as obese at week 68, compared to none in the placebo group. The company plans to present detailed results at ObesityWeek 2026. Shares closed at $46.60 on NYSE.